Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | NNMT | P40261 | 2/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | WEE1 | P30291 | 2/20 | 0.38 |
| ▸ | MYT1 | Q01538 | 2/20 | 0.38 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13824470 | 0.81 | PIM1 (0.42) | PIM1NNMTDGAT1KDM4EL3MBTL1 | |
| SCHEMBL12488275 | 0.81 | PIM1 (0.42) | NOS3NOS1NOS2PIM1NNMT | |
| SCHEMBL2828385 | 0.81 | PIM1 (0.50) | PIM1NNMTDGAT1KDM4EL3MBTL1 | |
| SCHEMBL3580429 | 0.80 | NOS3 (0.43) | NOS3NOS1NOS2KDM4EL3MBTL1 | |
| SCHEMBL701941 | 0.80 | KDM4E (0.60) | NOS3NOS1NOS2KDM4EL3MBTL1 | |
| SCHEMBL26684509 | 0.79 | PIM1 (0.41) | PIM1NNMTDGAT1KDM4ELMNA | |
| Hydrochloric Acid SCHEMBL28633319 | 0.79 | PIM1 (0.41) | PIM1NNMTDGAT1KDM4ELMNA | |
| SCHEMBL2254372 | 0.79 | POLB (0.47) | PIM1NNMTDGAT1L3MBTL1LMNA | |
| SCHEMBL31507586 | 0.79 | PIM1 (0.41) | PIM1NNMTDGAT1KDM4ELMNA | |
| SCHEMBL15890320 | 0.79 | DGAT1 (0.42) | PIM1NNMTDGAT1LMNASIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111868037-A | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2020-10-30 | — | — | CN | claimed |
| US-9701691-B2 | Thienopyrimidine compounds | HOFFMAN-LA ROCHE INC. (US) | 2017-07-11 | — | — | US | claimed |
| EP-2802590-B1 | THIENOPYRIMIDINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2017-03-01 | — | — | EP | claimed |
| EP-2802590-A1 | THIENOPYRIMIDINE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2014-11-19 | — | — | EP | claimed |
| WO-2013104575-A1 | THIENOPYRIMIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-18 | — | — | WO | claimed |
| US-20130178460-A1 | THIENOPYRIMIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | claimed |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | claimed |
| EP-0921800-A4 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL MYERS SQUIBB CO (US) | 2000-12-06 | — | — | EP | claimed |
| EP-0921800-A1 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-06-16 | — | — | EP | claimed |
| WO-1997029748-A1 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-08-21 | — | — | WO | claimed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| WO-2023122140-A1 | PARP1 INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| CN-115768760-A | Quinoxaline derivatives as anti-cancer agents | 阿斯利康(瑞典)有限公司 | 2023-03-07 | — | — | CN | disclosed |
| CN-115715194-A | Methods of treating coronavirus disease 2019 | 辉瑞公司 | 2023-02-24 | — | — | CN | disclosed |
| CN-114728941-A | Substituted 1, 5-naphthyridines or quinolines as ALK5 inhibitors | 施万生物制药研发IP有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-2802590-A1 | THIENOPYRIMIDINE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2014-11-19 | — | — | EP | disclosed |
| WO-2013104575-A1 | THIENOPYRIMIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-18 | — | — | WO | disclosed |
| US-20130178460-A1 | THIENOPYRIMIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20100069374-A1 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| WO-2009072643-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069374-A1 | Tricyclic benzopyrane compound | CBR1, CBR3, CYP2C9 | NOS3 943/4885NOS1 1819/4885NOS2 2004/4885 |
| US-20130178460-A1 | THIENOPYRIMIDINE COMPOUNDS | SYK, BTK, LCK | NOS3 1977/4885NOS1 1238/4885NOS2 1193/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | NOS3 3425/4885NOS1 3662/4885NOS2 3629/4885 |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | HRH3, HRH4, HRH1 | NOS3 3498/4885NOS1 4173/4885NOS2 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.